Botanix Pharmaceuticals Ltd
ASX:BOT
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
0.14
0.435
|
| Price Target |
|
We'll email you a reminder when the closing price reaches AUD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Botanix Pharmaceuticals Ltd
Botanix Pharmaceuticals Ltd
Cash & Cash Equivalents
Botanix Pharmaceuticals Ltd
Cash & Cash Equivalents Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash & Cash Equivalents | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Botanix Pharmaceuticals Ltd
ASX:BOT
|
Cash & Cash Equivalents
AU$79.3m
|
CAGR 3-Years
54%
|
CAGR 5-Years
76%
|
CAGR 10-Years
41%
|
|
|
Mayne Pharma Group Ltd
ASX:MYX
|
Cash & Cash Equivalents
AU$110.1m
|
CAGR 3-Years
4%
|
CAGR 5-Years
4%
|
CAGR 10-Years
N/A
|
|
|
Neuren Pharmaceuticals Ltd
ASX:NEU
|
Cash & Cash Equivalents
AU$2.6m
|
CAGR 3-Years
-48%
|
CAGR 5-Years
-32%
|
CAGR 10-Years
-19%
|
|
|
Probiotec Ltd
ASX:PBP
|
Cash & Cash Equivalents
AU$12.8m
|
CAGR 3-Years
-10%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
34%
|
|
|
Vita Life Sciences Ltd
ASX:VLS
|
Cash & Cash Equivalents
AU$27.7m
|
CAGR 3-Years
21%
|
CAGR 5-Years
24%
|
CAGR 10-Years
11%
|
|
|
Arovella Therapeutics Ltd
ASX:ALA
|
Cash & Cash Equivalents
AU$12.7m
|
CAGR 3-Years
24%
|
CAGR 5-Years
24%
|
CAGR 10-Years
N/A
|
|
Botanix Pharmaceuticals Ltd
Glance View
Botanix Pharmaceuticals Ltd. engages in the development of therapeutics for the treatment of skin diseases. The company is headquartered in Perth, Western Australia. The firm's product pipelines are based on drug delivery technology known as Permetrex. Its product pipeline consists of three clinical programs, which are using synthetic cannabidiol in the topical treatment of serious skin diseases and for antimicrobial applications. Its product pipeline includes BTX 1503 Gel, BTX 1702 Solution and BTX 1801 Ointment. Its BTX1503 Gel is a transdermal gel formulation for the treatment of serious acne in adults and teenagers. Its BTX 1702 Solution is used for the treatment of papulopustular rosacea. Its BTX 1801 Ointment is an antimicrobial gel focused on targeting Staphylococcus Aureus and Methicillin Resistant Staphylococcus Aureus (MRSA). The firm also has a chemistry program to identify, synthesize and test chemical entities that are related to naturally occurring cannabinoids.
See Also
What is Botanix Pharmaceuticals Ltd's Cash & Cash Equivalents?
Cash & Cash Equivalents
79.3m
AUD
Based on the financial report for Jun 30, 2024, Botanix Pharmaceuticals Ltd's Cash & Cash Equivalents amounts to 79.3m AUD.
What is Botanix Pharmaceuticals Ltd's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 10Y
41%
Over the last year, the Cash & Cash Equivalents growth was 674%. The average annual Cash & Cash Equivalents growth rates for Botanix Pharmaceuticals Ltd have been 54% over the past three years , 76% over the past five years , and 41% over the past ten years .
You don't have any saved screeners yet
